Sign in
WithdrawnNo phase

A Retrospective Study to Describe Real-World Treatment Patterns and Clinical Outcomes Among Patients With Myelodysplastic Syndromes

Key facts

Who runs it
Bristol-Myers Squibb
Where
Taiwan1 site in 1 countryChoose a country to see its sites
Trial code
Status
Withdrawn
Started
30 Nov 2024
Ended
30 Mar 2025
Type of study
Observational, 2 groups
Treatments tested
  • Luspatercept
  • Epoetin Alfa
Record updated
9 October 2024
Why it stopped
Sponsor decision

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Participant was enrolled in and discontinued the COMMANDS trial
  • Participant was treated with either luspatercept or epoetin alfa and discontinued treatment while enrolled in the COMMANDS trial
  • Participant Patient provides informed consent (only where applicable or required by local regulations)

Who cannot take part

  • There are no exclusion criteria for this study

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study aims to collect real-world data on treatment patterns and clinical outcomes for participants who discontinued Luspatercept or epoetin alfa treatment and discontinued the COMMANDS trial (NCT03682536) utilizing existing data from patient medical records.

The 2 groups in the trial

  • Luspatercept

    Adult participants treated with and discontinued Luspatercept treatment while enrolled in the COMMANDS trial (NCT03682536).

  • Epoetin alfa

    Adult participants treated with and discontinued Epoetin alfa treatment while enrolled in the COMMANDS trial (NCT03682536).

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Retrospective Study to Describe Real-World Treatment Patterns and Clinical Outcomes Among Patients With Myelodysplastic Syndromes Who Discontinued Treatment With Luspatercept or Epoetin Alfa and the COMMANDS Trial
Record updated
9 October 2024